№ lp_2_3_28193
File format: docx
Character count: 3260
File size: 141 KB
This document presents analytical methods for quantifying GS and GP in concentrated GJ granules using HPLC-UV.
Note:
Year
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Geesthacht, Dresden, New Delhi
Field:
Environmental Engineering, Wastewater Recycling
Document Type:
Research Article
Institution:
Helmholtz-Zentrum Hereon, Helmholtz-Zentrum Dresden-Rossendorf, Indian Institute of Technology Delhi
Author:
Aratrika Ghosh, Sarah Glass, Elsayed Gadelrib, Volkan Filiz, Rohan Jain
Target Audience:
Researchers, Environmental Engineers, Wastewater Management Professionals
Period of Validity:
Not specified
Date of Approval:
Not specified
Date of Amendments:
Not specified
Year:
2019
Region / city:
Australia, New Zealand
Theme:
Food safety
Document type:
Notification
Agency:
Food Standards Australia New Zealand (FSANZ)
Target audience:
WTO members, food industry
Period of validity:
From December 2019
Date of approval:
12 December 2019
Date of amendments:
N/A
Description:
The document informs about a temporary ban on the retail sale of foods containing high levels of caffeine in Australia and New Zealand, following health risks related to pure caffeine ingestion.
Year:
2019
Region / City:
Hermel, Lebanon
Topic:
Renewable Energy / Concentrated Solar Power
Document Type:
Request for Proposal (RFP)
Organization:
Lebanese Center for Energy Conservation (LCEC)
Author:
Lebanese Center for Energy Conservation (LCEC)
Target Audience:
Consultancy firms and joint ventures in energy sector
Submission Deadline:
26 November 2019
Contract Scope:
Feasibility study, technical, financial and economic assessment, capacity development, Environmental and Social Impact Assessment (ESIA), funding options, tender documents
Funding Agency:
Netherlands Enterprise Agency (RVO)
Supervision:
LCEC with coordination from Ministry of Energy and Water (MEW)
Technical Specifications:
Included in annexes
Proposal Validity:
210 days from submission date
Note:
Year
ISO Common Name:
Ametryn
Chemical Name:
4-N-ethyl-6-methylsulfanyl-2-N-propan-2-yl-1,3,5-triazine-diamine
Empirical Formula:
C9H17N5S
Relative Molecular Mass:
227.33
Boiling Point:
about 248°C (decomposition)
CAS Number:
834-12-8
CIPAC Code:
133
Method Status:
Provisional CIPAC method 2020
Based on:
Method supplied by Syngenta Crop Protection, USA
Document Type:
Analytical method
Analyte:
Ametryn
Formulations Covered:
Technical material (TC), Water Dispersible Granules (WG), Suspension Concentrates (SC)
Analytical Technique:
Capillary gas chromatography with flame ionization detection
Identity Tests:
Infrared spectrometry; Gas-liquid chromatography
Sampling Requirements:
Minimum 250 g (TC, WG) or 250 ml (SC)
Repeatability (TC):
10–13 g/kg at 968–972 g/kg
Reproducibility (TC):
19–20 g/kg at 968–972 g/kg
Repeatability (WG):
14 g/kg at 795 g/kg
Reproducibility (WG):
34 g/kg at 795 g/kg
Repeatability (SC):
7.7–10 g/kg at 435–447 g/kg
Reproducibility (SC):
19–20 g/kg at 435–447 g/kg
Year:
2025
Region / City:
Australia
Topic:
Cystic fibrosis treatment
Document Type:
Submission for listing in Section 100, Highly Specialised Drugs Program
Organization:
Vertex Pharmaceuticals Pty Ltd
Author:
Vertex Pharmaceuticals Pty Ltd
Target Audience:
Healthcare professionals, Medical practitioners
Effective Date:
February 6, 2025
Date of Last Consideration:
November 2023
Treatment Phase:
Initial treatment, Continuing treatment
Indication:
Cystic fibrosis
Population:
Patients aged 1 to 4 months with specific mutations in CFTR gene
Clinical Criteria:
Must be assessed through a cystic fibrosis clinic/center, G551D mutation or other gating mutations in CFTR gene
Prescription Type:
Authority Required
Date of Submission:
5 October 2025
Modification Date:
Not specified
Status:
Registered
Listing Request Basis:
Clinical need, equity
Background:
Ivacaftor approved for treatment of CF
Context Description:
A submission for listing a new strength of ivacaftor (13.4 mg granules) for cystic fibrosis patients aged 1 to 4 months with specific CFTR gene mutations, requesting inclusion in the Highly Specialised Drugs Program.
Year:
2026
Region / City:
Kent, Aylesford
Topic:
Safety and Hazard Assessment
Document Type:
Risk Assessment
Organization / Institution:
Guest Medical Limited
Author:
Pete Reynolds
Target Audience:
Employees, Sub-contractors, Public
Validity Period:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Control Measures:
Use in well ventilated areas
Personal Protective Equipment:
Dust mask, Visor, Goggles, Gloves, Overalls, Footwear
Health Surveillance Required:
Yes
Exposure Adequately Controlled:
Yes
Risk Rating:
High
Context:
Risk assessment of HAZ-TAB Granules, including safety and health risks, exposure controls, and required personal protective equipment for handling hazardous substances in the workplace.
Medicinal Product:
Hydrocortisone granules in capsules 0.5 mg, 1 mg, 2 mg, 5 mg (Alkindi®)
Sponsor:
Chiesi Australia
Regulatory Status:
Registered in the ARTG by the TGA on 18 August 2020
Orphan Drug Status:
Granted by the TGA
Submission Type:
Category 3 submission
Requested Listing:
Authority Required (STREAMLINED), General Schedule (Code GE)
Indication:
Replacement therapy of adrenal insufficiency
Population Criteria:
Patients diagnosed and initiated on treatment at 6 years of age or less; or patients 6 years of age or older with difficulty swallowing hydrocortisone tablets resulting in poor treatment compliance
Comparator:
Hydrocortisone 4 mg and 20 mg tablets (Hydrocortisone Mylan 4®, Hysone 4®, Hydrocortisone Mylan 20®, Hysone 20®)
Legislative Framework:
Section 101(3B) of the National Health Act 1953
Clinical Studies:
Infacort 001; Infacort 003; Infacort 004
Hearing:
No sponsor hearing conducted
Consumer Input:
Comments received from individuals, health care professionals and organisations via the PBS website
Economic Analysis:
Not presented
Authors:
Tony Malmqvist; Karen Anthony; Jean-Marc Gallo
Affiliation:
Department of Clinical Neuroscience, King’s College London, Institute of Psychiatry, London, United Kingdom
Corresponding Author:
Jean-Marc Gallo
Institutional Address:
King’s College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, United Kingdom
Type of Document:
Scientific research article
Field of Study:
Neuroscience; Molecular and Cellular Biology
Research Subject:
Localization and translation of tau mRNA in rat cortical neurons
Biological Material:
Primary rat cortical neurons
Key Methods:
Fluorescence in situ hybridization (FISH); RNA staining; immunocytochemistry
Key Molecules:
Tau mRNA; eukaryotic elongation factor 1A (eEF1A); neurofilament heavy subunit (NF-H)
Geographical Context:
London, United Kingdom
Institutional Context:
King’s College London, Institute of Psychiatry
Language:
English